A fourth generation luteinizing hormone releasing hormone (LHRH) antagonist


Market Opportunities

Ozarelix is a Luteinizing Hormone Releasing Hormone (LHRH) antagonist (a substance that blocks the effects of a natural hormone found in the body).

Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore be expected to be effective in a variety of hormonally dependent disease states including ovarian cancer, prostate cancer, BPH, infertility, uterine myoma and endometriosis.

Target Indications
  • Hormone-dependent prostate cancer
  • Endometriosis
  • Ovarian Cancer
Route of Administration
  • Intramuscular
  • Subcutaneous
Mode of Action
  • Luteinizing hormone releasing hormone antagonist
  • Suppression of testosterone and pituitary hormones
Drug Properties

To date, clinical trials with Ozarelix have shown:

  • Dose-dependent suppression of testosterone levels
  • No risk of testosterone surge or clinical flare
  • Improved solubility compared to other antagonists in the same class
  • Phase 2 trials

Ozarelix has the potential to be an important addition in treating hormone-dependent prostate cancer patients due to its ability to induce prolonged testosterone suppression without inducing an initial testosterone surge and associated risk of clinical flare and cancer progression observed in currently marketed LHRH agonists, as shown in healthy volunteers in early trials.

Ozarelix is available for out-licensing in India.